Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis

NCT03706040 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03706040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03706040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
December 27, 2018
Completion date
April 26, 2021
Enrollment
172 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis